about
Systems pharmacology: network analysis to identify multiscale mechanisms of drug actionSystems pharmacology of complex diseaseshERG channel function: beyond long QTThe emerging paradigm of network medicine in the study of human diseaseDEGAS: de novo discovery of dysregulated pathways in human diseasesAutomatic filtering and substantiation of drug safety signalsA target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLIntegrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitorsPrediction of drug-target interactions for drug repositioning only based on genomic expression similarityTowards structural systems pharmacology to study complex diseases and personalized medicineHarnessing Big Data for Systems PharmacologyCardiac models in drug discovery and development: a review.Computational models reduce complexity and accelerate insight into cardiac signaling networksLean Big Data integration in systems biology and systems pharmacology.An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndromeDecoding the complex genetic causes of heart diseases using systems biologyMolecular Targets and Associated Potential Pathways of Danlu Capsules in Hyperplasia of Mammary Glands Based on Systems PharmacologyActivation of human ether-a-go-go related gene (hERG) potassium channels by small moleculesDrosophila KCNQ channel displays evolutionarily conserved electrophysiology and pharmacology with mammalian KCNQ channels.Identification of hub genes related to the recovery phase of irradiation injury by microarray and integrated gene network analysis.Cardiac Arrhythmia: In vivo screening in the zebrafish to overcome complexity in drug discoveryRole of systems pharmacology in understanding drug adverse events.Whole-exome sequencing in familial atrial fibrillation.Cluster-based assessment of protein-protein interaction confidenceCALM3 mutation associated with long QT syndromeSystems pharmacology augments drug safety surveillanceA chemo-centric view of human health and diseaseSystems biology of kidney diseases.Implementation of quantitative and systems pharmacology in large pharma.A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointesA new method to improve network topological similarity search: applied to fold recognitionPhenome-driven disease genetics prediction toward drug discovery.Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms.Vitexicarpin acts as a novel angiogenesis inhibitor and its target networkExome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long QT syndrome.Therapeutic use of traditional Chinese herbal medications for chronic kidney diseasesModeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells.Systems pharmacology of adverse event mitigation by drug combinationsComputation as the mechanistic bridge between precision medicine and systems therapeutics.
P2860
Q26824166-7C83F642-F2C2-43CE-B9AC-0F4773D48A65Q26830739-6AEB3478-C98B-4FCA-A5D5-8D214AD72046Q27008078-19D9E2B4-3655-466B-890A-AA0A43BF7DD3Q27026041-FBCFF829-8A98-4A53-96A0-C4ADF5F8B5D9Q28475850-4A742FD6-6B5A-40DD-93E9-8AC630FEFA18Q28482131-2E0996AF-0F9C-4875-88EE-959F76E56F77Q28534337-50CFF5FD-36A7-489D-A4C9-10F609891A3FQ28534789-92F682C0-8E4E-4362-9CCE-D3C3BA319626Q28534907-9C91A995-BD94-417F-BFA0-66D3C15F3083Q28538838-05CB5CF9-4286-4746-905F-152A1CEFA127Q28969528-ED825BC8-2F21-4EF7-B56B-5B0898A5C0E3Q30426852-AC11825B-0661-47CE-9D61-32F4ACCBBFBAQ30428985-55424C54-3FF1-46F9-9A04-9D91D430254FQ30841748-7AF6EA3B-B1F9-4A73-B6A1-FCB9F98C9530Q31043880-3C98513B-1D2F-4543-9B4C-C49C9CF27D85Q33601622-D7D95ED9-2A0A-45A7-9CA1-E373EB5363DFQ33639681-BC460963-069C-4A28-87C3-2A5CAA0F7FE4Q33767905-F7C26990-9EA2-4535-A16E-96FAA2EFE4ACQ33859184-CC515C70-8F66-4137-B9EB-4D1F9D4EE42FQ34018870-BA458E6D-845D-4AEF-B180-2DEC3954A718Q34023904-46B42B89-0C85-4FF7-85D6-BBE42543EA6EQ34111355-A570630B-D4B1-409C-B8DE-37BDCB4AB940Q34134791-A36D783D-25C0-4787-837F-610C4A517B6CQ34217688-C87ACB23-7D27-4CE9-A078-CCA18D886FB4Q34438940-5B809F6C-EF7C-462B-9F48-F4D9F1CF40BDQ34451319-F8DCB201-114A-43C0-8F77-1709C49BCF8BQ35075939-D6D5BF91-56E2-4CF3-AFAC-779A1F549CDAQ35114229-89B4476C-95A5-477A-A2F9-268C5A6389D1Q35619034-6C73BC10-36E3-4AD4-AE52-03681FBE2A4CQ35760137-40939F24-BEBB-48DA-AC4A-9315580803C7Q35783016-AC21B949-DBAF-4D33-A458-CE7342E0BDD7Q35785428-29FA87A1-CB15-4531-962A-3A56CC95EFA2Q35975061-B16D417A-DD4B-4D34-A7BA-23B8E3B60E60Q36599215-EDC297D0-2FAA-475F-B6B8-0BACF770BF34Q36641099-1644FA0B-0828-4ADE-BF98-6243BE0A7F1EQ37140014-1A1E64A7-B9B5-4B1B-8A92-94D8F63765C3Q37266130-9E45DD2F-B4EC-4046-9A56-7F1057BD2E08Q37613893-CA6E7D3F-B398-416D-A447-E20C3FDCB3B9Q37658567-158C3A87-E8A5-4DD0-BC08-25AA1A7ABA22Q37658574-DA69D823-5C14-426A-9ED9-22D97B7B4F68
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Systems pharmacology of arrhythmias
@ast
Systems pharmacology of arrhythmias
@en
Systems pharmacology of arrhythmias
@nl
type
label
Systems pharmacology of arrhythmias
@ast
Systems pharmacology of arrhythmias
@en
Systems pharmacology of arrhythmias
@nl
prefLabel
Systems pharmacology of arrhythmias
@ast
Systems pharmacology of arrhythmias
@en
Systems pharmacology of arrhythmias
@nl
P2860
P1433
P1476
Systems pharmacology of arrhythmias
@en
P2093
Ravi Iyengar
P2860
P356
10.1126/SCISIGNAL.2000723
P577
2010-04-20T00:00:00Z